Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition
Poseida Therapeutics announced that preclinical data for its gene therapy P-FVIII-101 will be presented at the 64th ASH Annual Meeting on December 11, 2022. The therapy targets Hemophilia A and uses a non-viral delivery system, showing sustained Factor VIII activity for over six months in mouse models. This presentation illustrates the potential for P-FVIII-101 to provide a durable treatment solution. The P-FVIII-101 program is in collaboration with Takeda, highlighting Poseida’s innovative approach to gene therapy.
- P-FVIII-101 shows sustained Factor VIII activity for over six months in mouse models.
- Potential for single treatment cures with lower toxicity and safety concerns.
- Collaboration with Takeda enhances credibility and potential market reach.
- Results are still in preclinical stages, with no clinical trial data available yet.
Preclinical data to be presented highlight sustained and normalized Factor VIII activity following single dose of P-FVIII-101 for the treatment of Hemophilia A
SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that preclinical data from its P-FVIII-101 program, partnered with Takeda, has been selected for an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, being held in New Orleans and virtually December 10–13, 2022.
P-FVIII-101 is a liver-directed gene therapy product candidate for the in vivo treatment of Hemophilia A utilizing the Company's non-viral piggyBac® DNA Delivery System combined with its nanoparticle delivery technology. Compared to current generation gene therapy approaches that use traditional adeno-associated virus (AAV), the Company's non-viral gene delivery strategy is designed to enable potential single treatment cures with lower toxicity to mitigate safety issues, allow for re-dosing if needed and deliver optimized FVIII transgenes without cargo size limitations.
The oral presentation will highlight preclinical data from initial proof-of-concept studies, which demonstrated that a single administration of P-FVIII-101 resulted in durable expression of the Factor VIII protein at therapeutic levels in a dose-responsive manner. Expression of Factor VIII was shown to be sustained over six months in mouse models. These data illustrate the potential of P-FVIII-101 utilizing piggyBac to provide a long-term durable response for the treatment of Hemophilia A, early in life, with stable integration.
Details of the presentation are as follows:
Title: Sustained Factor VIII Activity Following Single Dose of Non-Viral Integrating Gene Therapy
Presenter: Brian Truong, Ph.D.
Presentation Date and Time: Sunday, December 11, 2022 at 10:15 AM ET
Session Name: 321. Coagulation and Fibrinolysis: Basic and Translational
Publication Number: 400
Location: Ernest N. Morial Convention Center, 293-294
The presentation will also be available to meeting attendees through the ASH virtual meeting platform.
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit www.poseida.com and connect with us on Twitter and LinkedIn.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, expected timing and plans with respect to clinical trials; the potential benefits of Poseida's technology platforms and product candidates; Poseida's plans and strategy with respect to developing its technologies and product candidates; and Poseida's ability to prioritize and utilize its resources efficiently and expected benefits from any such prioritization. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, Poseida's reliance on third parties for various aspects of its business; risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry; Poseida's ability to retain key scientific or management personnel; and the other risks described in Poseida's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-oral-presentation-highlighting-p-fviii-101-gene-therapy-at-the-64th-ash-annual-meeting--exposition-301667029.html
SOURCE Poseida Therapeutics, Inc.
FAQ
What is P-FVIII-101 and its significance for Hemophilia A treatment?
When will the P-FVIII-101 data be presented at the ASH Annual Meeting?
What are the potential benefits of the non-viral delivery system used in P-FVIII-101?
What is the collaboration between Poseida and Takeda regarding P-FVIII-101?
What does the preclinical data say about the efficacy of P-FVIII-101?
